Welcome to our dedicated page for Lyell Immunopharma SEC filings (Ticker: LYEL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Lyell Immunopharma filings document the regulatory record of a Nasdaq-listed clinical biotechnology company developing next-generation CAR T-cell therapies. Its 8-K reports furnish operating results and business updates for ronde-cel in large B-cell lymphoma and LYL273 in metastatic colorectal cancer and other GCC-expressing cancers, along with cash, financing and clinical-program disclosures.
The company’s filings also cover material agreements, including licensing rights for LYL273, and governance matters such as annual-meeting proposals, director elections, auditor ratification, executive compensation votes, officer appointments and compensatory arrangements. Securities disclosures identify Lyell’s common stock listed on the Nasdaq Global Select Market.
Innovative Cellular Therapeutics Holdings Ltd, a major shareholder of Lyell Immunopharma, Inc., reported an internal share transfer classified as an "other" transaction. On June 29, it transferred 76,000 shares of Common Stock to Wuxiong, Inc. as broker commission related to an upfront payment under a prior license agreement, for no cash consideration.
Following this restructuring-type transfer, the reporting holder now beneficially owns 2,857,500 shares of Lyell common stock, down from 2,933,500 shares immediately before the transaction. The filing reflects a non-market, compensation-related movement of shares rather than an open-market purchase or sale.
Innovative Cellular Therapeutics Holdings Ltd, a 10% owner of Lyell Immunopharma, Inc., transferred 66,500 shares of common stock on June 15, 2026 to LifeSci Advisors, LLC as broker commission tied to an upfront payment under a license agreement. The transfer was made for no cash consideration and reported as an “other” transaction. Following this move, the reporting holder directly beneficially owns 2,933,500 shares of Lyell common stock.
Innovative Cellular Therapeutics Holdings Limited reports it beneficially owns 3,000,000 shares of Lyell Immunopharma common stock, equal to approximately 12.3% of the class. The reporting person states it became entitled to an additional 1,100,000 shares upon achieving a development milestone under a License Agreement on 05/18/2026.
The filing amends a prior Schedule 13G/A and updates the beneficial ownership totals and voting/dispositive powers; the Reporting Person reports sole voting and dispositive power over the 3,000,000 shares.
Innovative Cellular Therapeutics Holdings Ltd has filed an initial ownership report showing it holds 3,000,000 shares of Lyell Immunopharma, Inc. common stock. These shares reflect equity consideration under a License Agreement between the two companies.
The position consists of 1,900,000 shares received as partial upfront consideration under a License Agreement dated November 6, 2025, and 1,100,000 shares tied to a development milestone achieved on May 18, 2026. Beneficial ownership is deemed acquired when the right to receive the milestone shares became fixed, and all shares are held of record by the reporting entity.
Lyell Immunopharma, Inc. President and CEO Lynn Seely reported a small stock transaction related to taxes on equity compensation. On May 11, 2026, 388 shares of common stock were sold at a weighted average price of $18.91 per share to cover a tax withholding obligation from the settlement of vested restricted stock units. After this tax-related sale, Seely directly holds 73,878 shares of Lyell Immunopharma common stock, indicating that the transaction affects only a very small portion of her overall holdings and reflects a routine administrative disposition rather than a discretionary portfolio change.
Lyell Immunopharma, Inc. Chief Scientific Officer Gary K. Lee reported an automatic share sale tied to tax withholding. On May 11, 2026, 130 shares of common stock were sold at a weighted average price of $18.92 per share to cover tax obligations from the settlement of vested restricted stock units.
After this transaction, Lee directly held 17,808 shares of Lyell Immunopharma common stock. This total includes 1,000 shares acquired on May 18, 2026 under the company’s 2021 Employee Stock Purchase Plan, indicating that the filing reflects both routine compensation-related activity and associated tax withholding.
Lyell Immunopharma, Inc. Chief Operating Officer Stephen J. Hill reported an automatic sale of 89 shares of common stock on May 11, 2026 at a weighted average price of $18.92 per share. The shares were sold to cover tax withholding obligations from the settlement of vested restricted stock units. After this tax-related sale, Hill directly held 17,894 shares of Lyell Immunopharma common stock.
Lyell Immunopharma, Inc. VP and Corporate Controller Veronica Sanchez Bulis reported a small open-market sale of company common stock. She sold 217 shares on May 11, 2026, automatically to cover a tax withholding obligation from the settlement of vested restricted stock units.
The shares were sold at a weighted average price between $18.91 and $19.30 per share. After this tax-related sale, she directly owns 15,420 shares of Lyell Immunopharma common stock.
Lyell Immunopharma, Inc. reported the voting results from its 2026 annual meeting of stockholders. A quorum was established, with 15,706,826 shares represented, equal to 67.31% of the 23,332,254 shares outstanding as of April 14, 2026.
Stockholders elected Richard Klausner, M.D., Otis Brawley, M.D., and William Rieflin to the board, each receiving more than 11.8 million votes in favor. Stockholders also approved a proposal with 15,674,347 votes for and 30,758 against, and an additional proposal received 11,860,218 votes for and 3,429,286 broker non-votes.
Lyell Immunopharma director William JL Rieflin received a new stock option grant for 9,250 shares of common stock. The option has an exercise price of $13.22 per share and expires on June 9, 2036.
According to the award terms, these option shares vest on the earlier of the next annual stockholder meeting following June 10, 2026 (or immediately before that meeting if his board service ends at that time) or the first anniversary of June 10, 2026, provided he continues serving through the vesting date. After this grant, his reported option holdings from this award total 9,250 shares.